Angiogenesis inhibitors, like bevacizumab, can effectively reduce tumor angiogenesis by inhibiting the VEGF signaling pathway, thereby significantly improving the prognosis of patients with BCBM. This evidence concerns the gene VEGFA and neoplasm.